Several drugmakers whose sales boomed on COVID-19 vaccines and related products in 2021 and 2022 have now been embroiled in a hangover…
McAlinden Research PartnersOctober 18, 2023
The FTC's settlement with Amgen and Horizon has cleared the way for the two companies to complete a $27.8 billion…
McAlinden Research PartnersSeptember 5, 2023
Some gauges indicate that foreign investment in China has sunken to 25-year lows recently. Beijing sees development of the country's biotechnology…
McAlinden Research PartnersAugust 15, 2023
Summary: Ongoing shortages of popular obesity-fighting drugs from Novo Nordisk represent the surging popularity of medication-based intervention as treatment. Though…
McAlinden Research PartnersJuly 25, 2023
New FDA guidance meant to steer clinical trials of psychedelic compounds will play a major role in the eventual approval…
McAlinden Research PartnersJuly 12, 2023
CRISPR gene editing therapies took a big step toward commercialization in the United States last week, as the FDA laid…
McAlinden Research PartnersJune 13, 2023
Shares of biotech firms focused on gene editing have been heating up this month, largely on the back of the…
McAlinden Research PartnersMay 25, 2023
Johnson & Johnson's most recent earnings data showed revenues and earnings per share growing more robustly than analysts anticipated. However,…
McAlinden Research PartnersApril 18, 2023
Pfizer's acquisition of Seagen, which is the largest biopharma deal since 2019, comes as products received in previous deals begin…
McAlinden Research PartnersMarch 14, 2023
